IBRX stock forecast tracks ImmunityBio’s cancer drug progress amid volatility, price at $9.78. Explore IBRX stock price, earnings surge, technical analysis, and if IBRX stock is a buy.
Introduction
ImmunityBio develops immunotherapies for cancer and infectious diseases. Investors eye IBRX stock now due to Anktiva trial milestones and revenue jumps. Biotech faces funding pressures and regulatory waits in 2026 markets.
Recent 700% growth news sparks buzz. This analysis uses last market close data from Feb 27, 2026.
Latest Stock Price & Trend
IBRX stock closed at $9.78 on Feb 27, 2026, up 2.41% from prior session. Pre-market dipped to $9.60 on Mar 2 amid profit-taking.
Five-day trend gained 15% on trial data. One-month soared 80% from $5.50 lows. Three months exploded 200%+ from year-end levels.
Six-month performance tripled; year-to-date up 325%. 52-week high $12.43, low $1.83. Bullish trend dominates, but volatility warns investors of sharp swings.
Technical Analysis
Support near $9.00-$9.50 holds recent lows—levels where buyers defend price. Resistance at $11.00-$12.00 caps rallies from prior highs.
RSI above 65 nears overbought (70+ signals potential pullbacks); under 30 marks oversold buys. MACD bullish with line above signal for momentum.
Golden cross active—50-day average crossed above 200-day, favoring uptrends. Volume surged to 38 million shares, double average, showing conviction.
These indicators flag entry points and exhaustion risks clearly.
Analyst Ratings & Price Targets
Five analysts rate IBRX stock Strong Buy. Average target $12.60, implying 28.83% upside from recent levels.
No recent downgrades; consensus builds on Anktiva data. Wall Street optimism reflects pipeline value for risk-tolerant investors.
Insider Activity
Insider buying quiet; minor sales in Q4 2025 totaled under $1 million per SEC records. Management holds steady positions.
Trends suggest confidence without aggressive moves. Low activity aligns with clinical focus over trading.
Valuation Analysis
Trailing P/E unavailable on losses; forward P/E high at 74.6x sales. Price-to-Sales extreme on $113.29 million TTM revenue, up 668% YoY.
EPS -0.38; net loss $351.40 million. Free cash flow negative from trials; cash position supports runway, debt manageable.
Vs biotech peers, IBRX stock looks overvalued on revenue but bets on approvals justify premium.
Recent Earnings & Catalysts
Full-year 2025 revenue exploded 700% to $113 million, beating views. Q4 hit $38 million, EPS -0.06 topped estimates.
Guidance eyes label expansions. Catalysts: Anktiva lung cancer approvals in 33 countries, trial enrollment complete.
Surprise growth lifted shares 471% earlier; volatility followed on profit-taking.
Bullish Case
Anktiva demand drives revenue ramps. Cancer immunotherapy market grows 12% yearly.
Global partnerships expand reach. Trial successes unlock commercialization steadily.
Bearish Case
FDA delays plague approvals. Competition in immunotherapy crowded.
Cash burn high at $351 million losses. Dilution risks via funding loom large.
Market Sentiment & Investor Psychology
Short interest elevated; options favor calls on retail flows. Institutions steady at mid-cap levels.
Retail chases momentum with 200%+ yearly gains. Sentiment optimistic, momentum bias strong.
Short-Term Outlook
Overbought RSI eyes tests at support. Volume cools post-spike.
Expect $9-$11 range absent news.
Medium to Long-Term Outlook
Pipeline strength hinges on Anktiva data. Biotech sector volatile but innovative.
Financials strain under trials; trial wins key advantage. Watch closely; accumulate select dips.
FAQ
Is IBRX stock a buy right now?
Strong Buy per analysts; high risk suits aggressive portfolios.
What is the price target for IBRX stock?
$12.60 average; end-2026 $12-$18 potential.
What are major risks for IBRX stock?
Trial failures, dilution, regulatory delays.
IBRX earnings outlook?
Revenue growth continues; profitability distant.
IBRX long term outlook?
Promising if Anktiva succeeds globally.
Suggestions
- Compare with Opendoor stocks
- See our Bristol Myers biotech forecast
- Read our cancer treatment pipeline analysis
Conclusion
Watchlist IBRX stock. Explosive revenue excites, but biotech risks demand caution—ideal for diversified speculative plays.
Disclaimer: This article is for informational purposes only and not financial advice.